Literature DB >> 23946605

Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China.

Ji-Yao Wang1, Ning-Ping Zhang, Bao-Rong Chi, Yu-Qing Mi, Li-Na Meng, Ying-Di Liu, Jiang-Bin Wang, Hai-Xing Jiang, Jin-Hui Yang, Yun Xu, Xiao Li, Jian-Ming Xu, Guo Zhang, Xin-Min Zhou, Yu-Zheng Zhuge, De-An Tian, Jin Ye, Yu-Lan Liu.   

Abstract

AIM: To investigate the prevalence of minimal hepatic encephalopathy (MHE) and to assess corresponding health-related quality of life (HRQoL) in hospitalized cirrhotic patients in China.
METHODS: This multi-center cross-sectional study included 16 teaching hospitals, which were members of "Hepatobiliary Cooperation Group, Society of Gastroenterology, Chinese Medical Association", from different areas of China carried out between June and October in 2011. All the eligible hospitalized cirrhotic patients (n = 538) were required to complete triplicate number connection tests combined with one digit symbol test for diagnosing MHE. Patients' clinical examination data were complemented by a modified questionnaire assessing HRQoL. Written informed consent was obtained from each patient.
RESULTS: Male was predominant (68.6%) in 519 patients who met the criteria of the study, with a mean age of 49.17 ± 11.02 years. The most common cause of liver cirrhosis was chronic hepatitis B (55.9%). The prevalence of MHE was 39.9% and varied by Child-Pugh-Classification score (CPC-A: 24.8%, CPC-B: 39.4% and CPC-C: 56.1%, P < 0.01). MHE (P < 0.01) and higher CPC scores (P < 0.01) were associated with a high HRQoL scores (reflecting poorer quality of life). The prevalence of MHE was proportionate to CPC (P = 0.01) and high quality of life scores (P = 0.01).
CONCLUSION: Hospitalized cirrhotic patients have a high prevalence of MHE that is proportionate to the degree of liver function and HRQoL impairment.

Entities:  

Keywords:  Child-Pugh Classification; China; Health-related quality of life; Liver cirrhosis; Minimal hepatic encephalopathy

Mesh:

Year:  2013        PMID: 23946605      PMCID: PMC3740430          DOI: 10.3748/wjg.v19.i30.4984

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  38 in total

1.  Interval estimation for Cohen's kappa as a measure of agreement.

Authors:  N J Blackman; J J Koval
Journal:  Stat Med       Date:  2000-03-15       Impact factor: 2.373

2.  Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy.

Authors:  R K Dhiman; M S Sawhney; Y K Chawla; G Das; S Ram; J B Dilawari
Journal:  Dig Dis Sci       Date:  2000-08       Impact factor: 3.199

3.  Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis.

Authors:  A Das; R K Dhiman; V A Saraswat; M Verma; S R Naik
Journal:  J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 4.029

Review 4.  New perspectives in hepatic encephalopathy.

Authors:  Kevin D Mullen; Ravi K Prakash
Journal:  Clin Liver Dis       Date:  2012-01-16       Impact factor: 6.126

5.  Factors associated with poor health-related quality of life of patients with cirrhosis.

Authors:  G Marchesini; G Bianchi; P Amodio; F Salerno; M Merli; C Panella; C Loguercio; G Apolone; M Niero; R Abbiati
Journal:  Gastroenterology       Date:  2001-01       Impact factor: 22.682

Review 6.  Quality of life in cirrhotics with minimal hepatic encephalopathy.

Authors:  H Schomerus; W Hamster
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

7.  Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy.

Authors:  M Romero-Gómez; F Boza; M S García-Valdecasas; E García; J Aguilar-Reina
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

8.  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Authors:  Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

9.  [An epidemiological survey of subclinical hepatic encephalopathy].

Authors:  Zheng Zeng; Yu-yuan Li; Yu-qiang Nie
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2003-11

10.  Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis.

Authors:  Miguel R Arguedas; Thomas G DeLawrence; Brendan M McGuire
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

View more
  16 in total

Review 1.  Advances in psychometric tests for screening minimal hepatic encephalopathy: From paper-and-pencil to computer-aided assessment.

Authors:  Ming Luo; Ping Ma; Lei Li; Wu-Kui Cao
Journal:  Turk J Gastroenterol       Date:  2019-05       Impact factor: 1.852

2.  Aberrant interhemispheric functional coordination in patients with HBV-related cirrhosis and minimal hepatic encephalopathy.

Authors:  Hua-Jun Chen; Yu Wang; Ming Yang; Xi-Qi Zhu; Gao-Jun Teng
Journal:  Metab Brain Dis       Date:  2014-02-20       Impact factor: 3.584

3.  Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.

Authors:  Masato Nakai; Goki Suda; Koji Ogawa; Sonoe Yoshida; Shunichi Hosoda; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Taku Shigesawa; Masatsugu Ohara; Takuya Sho; Kenichi Morikawa; Naoya Sakamoto
Journal:  PLoS One       Date:  2022-07-01       Impact factor: 3.752

4.  Management of hepatic encephalopathy.

Authors:  Jennifer A Frontera
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.598

5.  Psychometric hepatic encephalopathy score for diagnosis of minimal hepatic encephalopathy in China.

Authors:  Su-Wen Li; Kai Wang; Yong-Qiang Yu; Hai-Bao Wang; Yuan-Hai Li; Jian-Ming Xu
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

6.  Minimal Hepatic Encephalopathy and Biejia-Ruangan Are Associated with First Hospital Readmission in Nonalcoholic Cirrhosis Patients.

Authors:  Ting-Ting Jiang; Xiao-Li Liu; Yu-Yong Jiang; Xian-Bo Wang; Zhi-Yun Yang
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-07       Impact factor: 2.629

7.  Reversibility of minimal hepatic encephalopathy following liver transplantation in Egyptian cirrhotic patients.

Authors:  Mahmoud A Osman; Moataz M Sayed; Khaled A Mansour; Shereen A Saleh; Wesam A Ibrahim; Sara M Abdelhakam; Mohamed Bahaa; Wael A Yousry; Hosam S Elbaz; Reginia N Mikhail; Azza M Hassan; Ehab H Elsayed; Dalia A Mahmoud
Journal:  World J Hepatol       Date:  2016-10-28

8.  JianPi HuaZhuo XingNao formula (Chinese herbal medicine) for the treatment of minimal hepatic encephalopathy: a protocol for a randomized, placebo-controlled pilot trial.

Authors:  XiaoKe Li; DaNan Gan; Ying Li; Peng Zhang; ZhiGuo Li; HongBo Du; LuDan Zhang; Yuan Cheng; YaQiang Zhang; YiJun Liang; YongAn Ye
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

9.  EncephalApp Stroop App predicts poor sleep quality in patients with minimal hepatic encephalopathy due to hepatitis B-induced liver cirrhosis.

Authors:  Ming Luo; Xiao-Bing Yu; Sheng-Juan Hu; Fei-Hu Bai
Journal:  Saudi J Gastroenterol       Date:  2020 May-Jun       Impact factor: 2.485

10.  Natural history of covert hepatic encephalopathy: An observational study of 366 cirrhotic patients.

Authors:  An-Jiang Wang; A-Ping Peng; Bi-Min Li; Na Gan; Li Pei; Xue-Lian Zheng; Jun-Bo Hong; Hai-Ying Xiao; Jia-Wei Zhong; Xuan Zhu
Journal:  World J Gastroenterol       Date:  2017-09-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.